Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exact Sciences Corporation
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Number of employees : 5 000 people.
Sales per Business
2020
USD (in Million)%
Screening815.0754.7%
Precision Oncology440.4929.5%
COVID-19 Testing235.8315.8%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States864.8598.7%1,41494.8% +63.49%
Non-United States11.441.3%77.485.2% +577.07%
Managers and Directors
NameAgeSinceTitle
Kevin Conroy542014Chairman, President & Chief Executive Officer
Jeffrey Elliott422016Chief Financial Officer
Graham Lidgard712009Chief Science Officer, SVP-Research & Development
Sandra Statz-2012SVP-Clinical & Regulatory Affairs
Gary Frings-2015Chief Information Officer
Paul Limburg-2018Co-Chief Medical Officer
Scott Johnson-2017Senior Vice President-Research & Development
Steven Shak692019Co-Chief Medical Officer
Ana Hooker-2013Senior Vice President-Operations
Tim Caprez-2015Chief Compliance Counsel & Vice President
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 169,093,162 157,986,204 93.4% 0 0.0% 93.4%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 16,548,248 10.4%
The Vanguard Group, Inc. 14,200,093 8.93%
Capital Research & Management Co. (World Investors) 10,298,396 6.48%
JPMorgan Investment Management, Inc. 5,827,568 3.66%
Wellington Management Co. LLP 5,772,683 3.63%
ARK Investment Management LLC 5,312,466 3.34%
BlackRock Fund Advisors 3,836,817 2.41%
SSgA Funds Management, Inc. 3,462,138 2.18%
Artisan Partners LP 3,195,857 2.01%
Viking Global Investors LP 2,996,604 1.88%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exact Sciences Corporation
Sector Bio Diagnostics & Testing
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION2.94%21 402
GUARDANT HEALTH, INC.11.50%14 431
BGI GENOMICS CO., LTD.5.08%8 562
INVITAE CORPORATION-6.63%7 677
ADAPTIVE BIOTECHNOLOGIES CORPORATION-15.17%6 983
IOVANCE BIOTHERAPEUTICS, INC.-26.31%5 025
CAREDX, INC0.66%3 779
VERACYTE, INC.13.16%3 711
SEEGENE INC--.--%2 970
Q-LINEA AB (PUBL)-19.41%441
BIOVICA INTERNATIONAL AB (PUBL)-28.91%123
EPIGENOMICS AG-32.35%16